Pennsylvania House Bill HR123

Pennsylvania 2023-2024 Regular Session

• Introduced: 5/24/23
• Refer: 5/24/23
• Passed: 6/13/23

Caption

Recognizing June 29, 2023, as "World Scleroderma Day" in Pennsylvania.

Impact

The passage of HR123 has the potential to influence public health initiatives in Pennsylvania by encouraging state agencies, healthcare providers, and local communities to engage in awareness activities surrounding scleroderma. The resolution serves as a rallying point for advocacy groups and individuals affected by the disease, fostering a sense of community and shared purpose in addressing the challenges posed by scleroderma. It also opens the door for discussions related to the importance of research funding and healthcare policies aimed at supporting individuals living with this condition.

Summary

House Resolution 123 (HR123) aims to officially recognize June 29, 2023, as 'World Scleroderma Day' in Pennsylvania. The resolution seeks to bring awareness to scleroderma, a chronic disease that affects the skin and connective tissues, highlighting the importance of education and understanding of this condition. By designating a specific day for recognition, the bill intends to honor those affected by this disease and promote further research and support initiatives.

Sentiment

The sentiment surrounding HR123 is largely positive, with legislators recognizing the importance of supporting awareness for lesser-known diseases like scleroderma. The strong vote in favor of the resolution—with 202 yea votes and only 1 nay—demonstrates bipartisan support and indicates a collective understanding of the need to address health issues that impact a segment of the population significantly. This positivity underscores a commitment to public health and social responsibility.

Contention

While HR123 received overwhelming support, there could be underlying contentions regarding the allocation of resources for awareness and potential funding for research into scleroderma. The resolution does not mandate any specific funding or government action, which some may view as a limitation. The challenge will be to translate this recognition into actionable policies and programs that genuinely benefit those affected by scleroderma and promote better healthcare outcomes.